Complete Response in Metastatic Clear Cell Renal Cell Carcinoma Patients Treated with Immune-Checkpoint Inhibitors: Remission or Healing? How to Improve Patients’ Outcomes?
Renal-cell carcinoma (RCC) accounts for 2% of cancer diagnoses and deaths worldwide. Clear-cell RCCs represent the vast majority (85%) of kidney cancers and are considered morphologically and genetically as immunogenic tumors. Indeed, the RCC tumoral microenvironment comprises T cells and myeloid ce...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-01-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/3/793 |
| _version_ | 1797624980225130496 |
|---|---|
| author | Jonathan Thouvenin Claire Masson Philippe Boudier Denis Maillet Sabine Kuchler-Bopp Philippe Barthélémy Thierry Massfelder |
| author_facet | Jonathan Thouvenin Claire Masson Philippe Boudier Denis Maillet Sabine Kuchler-Bopp Philippe Barthélémy Thierry Massfelder |
| author_sort | Jonathan Thouvenin |
| collection | DOAJ |
| description | Renal-cell carcinoma (RCC) accounts for 2% of cancer diagnoses and deaths worldwide. Clear-cell RCCs represent the vast majority (85%) of kidney cancers and are considered morphologically and genetically as immunogenic tumors. Indeed, the RCC tumoral microenvironment comprises T cells and myeloid cells in an immunosuppressive state, providing an opportunity to restore their activity through immunotherapy. Standard first-line systemic treatment for metastatic patients includes immune-checkpoint inhibitors (ICIs) targeting PD1, in combination with either another ICI or with antiangiogenic targeted therapy. During the past few years, several combinations have been approved with an overall survival benefit and overall response rate that depend on the combination. Interestingly, some patients achieve prolonged complete responses, raising the question of whether these metastatic RCC patients can be cured. This review will focus on recent therapeutic advances in RCC and the clinical and biological aspects underpinning the potential for healing. |
| first_indexed | 2024-03-11T09:50:21Z |
| format | Article |
| id | doaj.art-aef9ef00ed95431ab60209355b3b445a |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T09:50:21Z |
| publishDate | 2023-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-aef9ef00ed95431ab60209355b3b445a2023-11-16T16:17:16ZengMDPI AGCancers2072-66942023-01-0115379310.3390/cancers15030793Complete Response in Metastatic Clear Cell Renal Cell Carcinoma Patients Treated with Immune-Checkpoint Inhibitors: Remission or Healing? How to Improve Patients’ Outcomes?Jonathan Thouvenin0Claire Masson1Philippe Boudier2Denis Maillet3Sabine Kuchler-Bopp4Philippe Barthélémy5Thierry Massfelder6Medical Oncology Department, Hospices Civils de Lyon, Hôpital Lyon Sud, 69310 Pierre-Bénite, FranceRegenerative NanoMedicine, Centre de Recherche en Biomédecine de Strasbourg, Fédération de Médecine Translationnelle de Strasbourg (FMTS), UMR_S U1260 INSERM, University of Strasbourg, 67085 Strasbourg, FranceMedical Oncology Department, Institut de Cancérologie Strasbourg Europe, 67200 Strasbourg, FranceMedical Oncology Department, Hospices Civils de Lyon, Hôpital Lyon Sud, 69310 Pierre-Bénite, FranceRegenerative NanoMedicine, Centre de Recherche en Biomédecine de Strasbourg, Fédération de Médecine Translationnelle de Strasbourg (FMTS), UMR_S U1260 INSERM, University of Strasbourg, 67085 Strasbourg, FranceMedical Oncology Department, Institut de Cancérologie Strasbourg Europe, 67200 Strasbourg, FranceRegenerative NanoMedicine, Centre de Recherche en Biomédecine de Strasbourg, Fédération de Médecine Translationnelle de Strasbourg (FMTS), UMR_S U1260 INSERM, University of Strasbourg, 67085 Strasbourg, FranceRenal-cell carcinoma (RCC) accounts for 2% of cancer diagnoses and deaths worldwide. Clear-cell RCCs represent the vast majority (85%) of kidney cancers and are considered morphologically and genetically as immunogenic tumors. Indeed, the RCC tumoral microenvironment comprises T cells and myeloid cells in an immunosuppressive state, providing an opportunity to restore their activity through immunotherapy. Standard first-line systemic treatment for metastatic patients includes immune-checkpoint inhibitors (ICIs) targeting PD1, in combination with either another ICI or with antiangiogenic targeted therapy. During the past few years, several combinations have been approved with an overall survival benefit and overall response rate that depend on the combination. Interestingly, some patients achieve prolonged complete responses, raising the question of whether these metastatic RCC patients can be cured. This review will focus on recent therapeutic advances in RCC and the clinical and biological aspects underpinning the potential for healing.https://www.mdpi.com/2072-6694/15/3/793clear-cell-renal-cell carcinomaimmune-checkpoint inhibitorsimmunotherapycomplete responsefirst-line treatment |
| spellingShingle | Jonathan Thouvenin Claire Masson Philippe Boudier Denis Maillet Sabine Kuchler-Bopp Philippe Barthélémy Thierry Massfelder Complete Response in Metastatic Clear Cell Renal Cell Carcinoma Patients Treated with Immune-Checkpoint Inhibitors: Remission or Healing? How to Improve Patients’ Outcomes? Cancers clear-cell-renal-cell carcinoma immune-checkpoint inhibitors immunotherapy complete response first-line treatment |
| title | Complete Response in Metastatic Clear Cell Renal Cell Carcinoma Patients Treated with Immune-Checkpoint Inhibitors: Remission or Healing? How to Improve Patients’ Outcomes? |
| title_full | Complete Response in Metastatic Clear Cell Renal Cell Carcinoma Patients Treated with Immune-Checkpoint Inhibitors: Remission or Healing? How to Improve Patients’ Outcomes? |
| title_fullStr | Complete Response in Metastatic Clear Cell Renal Cell Carcinoma Patients Treated with Immune-Checkpoint Inhibitors: Remission or Healing? How to Improve Patients’ Outcomes? |
| title_full_unstemmed | Complete Response in Metastatic Clear Cell Renal Cell Carcinoma Patients Treated with Immune-Checkpoint Inhibitors: Remission or Healing? How to Improve Patients’ Outcomes? |
| title_short | Complete Response in Metastatic Clear Cell Renal Cell Carcinoma Patients Treated with Immune-Checkpoint Inhibitors: Remission or Healing? How to Improve Patients’ Outcomes? |
| title_sort | complete response in metastatic clear cell renal cell carcinoma patients treated with immune checkpoint inhibitors remission or healing how to improve patients outcomes |
| topic | clear-cell-renal-cell carcinoma immune-checkpoint inhibitors immunotherapy complete response first-line treatment |
| url | https://www.mdpi.com/2072-6694/15/3/793 |
| work_keys_str_mv | AT jonathanthouvenin completeresponseinmetastaticclearcellrenalcellcarcinomapatientstreatedwithimmunecheckpointinhibitorsremissionorhealinghowtoimprovepatientsoutcomes AT clairemasson completeresponseinmetastaticclearcellrenalcellcarcinomapatientstreatedwithimmunecheckpointinhibitorsremissionorhealinghowtoimprovepatientsoutcomes AT philippeboudier completeresponseinmetastaticclearcellrenalcellcarcinomapatientstreatedwithimmunecheckpointinhibitorsremissionorhealinghowtoimprovepatientsoutcomes AT denismaillet completeresponseinmetastaticclearcellrenalcellcarcinomapatientstreatedwithimmunecheckpointinhibitorsremissionorhealinghowtoimprovepatientsoutcomes AT sabinekuchlerbopp completeresponseinmetastaticclearcellrenalcellcarcinomapatientstreatedwithimmunecheckpointinhibitorsremissionorhealinghowtoimprovepatientsoutcomes AT philippebarthelemy completeresponseinmetastaticclearcellrenalcellcarcinomapatientstreatedwithimmunecheckpointinhibitorsremissionorhealinghowtoimprovepatientsoutcomes AT thierrymassfelder completeresponseinmetastaticclearcellrenalcellcarcinomapatientstreatedwithimmunecheckpointinhibitorsremissionorhealinghowtoimprovepatientsoutcomes |